Drug intelligence / Profile preview

EBP-A.muc-LBP1

Development stage: Unknown
Lead developer: Enterobiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

EBP-A.muc-LBP1 is a live biotherapeutic product (LBP) candidate being developed by Enterobiome for the treatment of atopic dermatitis and allergic rhinitis. The product consists of a live strain of *Akkermansia muciniphila*, a keystone gut bacterium known for its role in maintaining intestinal barrier integrity and modulating host immune responses. EBP-A.muc-LBP1 is designed to leverage the gut-skin and gut-lung axes to suppress systemic inflammation and restore immune homeostasis in patients with allergic conditions. According to company pipeline information, the drug is progressing toward Phase 2 clinical development, with projected timelines indicating Phase 2 trials around 2028.

Other names: Enterobiome-A.muciniphila-LBP

Beyond the preview

Go deeper on EBP-A.muc-LBP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBP-A.muc-LBP1.

Explore the full profile